Skinvisible’s Revolutionizing Sunscreen Brand Skinbrella® Highlighted by Mediaplanet’s “Skin Cancer” Campaign

Share Article

Mediaplanet today proudly announces the release of its most recent cross-platform content marketing campaign, “Skin Cancer,” which urges those at risk to be mindful of proper sun protection practices, while educating themselves on some of the leading products and remedies on the market that will allow them to do so effectively.

News Image

In the New York, Chicago, Seattle, Phoenix, South Florida, Los Angeles, and Philadelphia markets, the print portion of “Skin Cancer” is distributed within the June 17 weekend edition of USA Today. With an estimated readership of 1.3 million, 450,000 copies will be circulating through these select high-impact markets. The digital portion of the campaign is distributed nationally, through an extensive social media strategy, and across top news sites and partner media outlets. To view the digital campaign, click here.

All year round, but particularly with the summer months ahead when skin exposure is at its peak, Mediaplanet is enlisting Skinvisible Pharmaceuticals, Inc., among others, to foster wider awareness about the importance of sun protection in the prevention of skin cancer.

Skinbrella is a broad spectrum, SPF 30 sunscreen made with the Company’s patented topical delivery technology Invisicare®. It provides 80 minutes of water resistance—the highest designation allowed by the FDA. It meets the requirements to be labeled “broad spectrum,” signifying that it provides both UVA and UVB protection. Skinbrella glides on smoothly without any sticky after feeling, while still allowing the skin to breath naturally. It will not run in your eyes when you perspire, making Skinbrella a truly “sports friendly” sunscreen. So whether you are a golfer, swimmer, hiker, or soccer mom, Skinbrella will protect you and your family.

Avobenzone, the only UVA absorber approved by the FDA, degrades in the sun in less than two hours resulting in less skin protection. Skinbrella conversely has proven to deliver eight hours of photostability of avobenzone, a unique advantage for which a patent was granted by the United States Patent and Trademark Office. The patent: “Sunscreen Composition With Enhanced UVA Absorber Stability and Methods,” Patent Number 8128913 proves the ability of Invisicare to stabilize avobenzone, one of the essential benefits of Skinbrella.

This campaign was made possible with support from Kintari USA Inc. and Skinvisible Pharmaceuticals, Inc., a leader in contributing to the health and well-being of people all over the world through the advancement of science and the discovery of new technologies.

For more information or to purchase Skinbrella, go to

About Skinvisible Pharmaceuticals, Inc. (SKVI: OTCQB)
Skinvisible Inc., is a science-based research and development company with a patented skin delivery technology Invisicare®, the foundation to every topical prescription (Rx), over-the-counter (OTC) and cosmeceutical product developed by Skinvisible. Skinvisible continues to build its worldwide patent portfolio while seeking licensees for its prescription line of dermatology focused products, while its wholly-owned subsidiary Kintari focuses exclusively on the marketing of OTC and cosmeceutical products. The Company has over fifteen patents worldwide and a portfolio of over forty products ready to be licensed or introduced to the marketplace.

About Mediaplanet
Mediaplanet is the leading publisher of specialized content-marketing campaigns touching on a variety of engaging topics and key industries. We turn reader interest into action by providing readers with inspiring editorial, aligning it with relevant advertising sponsorships and distributing it within top newspapers and online platforms throughout the world.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lindsay Dworetz
+1 646 922 1406
Email >
Follow >
Visit website